Shionogi & Co Ltd (4507):企業の財務・戦略的SWOT分析

◆英語タイトル:Shionogi & Co Ltd (4507) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C5002
◆発行会社(調査会社):GlobalData
◆発行日:2018年9月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Shionogi & Co Ltd (4507) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Shionogi & Co Ltd (Shionogi) focuses on the research, development, manufacturing and marketing of pharmaceutical products, diagnostic reagents and medical devices. The company’s core pharmaceuticals product business offers drugs for the treatment of disorders in the areas of metabolism, infection, immunity and cancer pain. Shionogi also sells, distributes and provides information about diagnostic products in the fields of infectious diseases, cardiovascular diseases and allergies. The company operates a network of subsidiaries, branches, sales offices manufacturing plants and research laboratories across Japan, China, Taiwan, North America and Europe. Shionogi is headquartered in Osaka, Japan.

Shionogi & Co Ltd Key Recent Developments

Sep 05,2018: Baloxavir Marboxil Phase II and III Studies for the Treatment of Influenza Published in the New England Journal of Medicine[Newswire : Healthcare-BW]
Aug 30,2018: TOPC : Shionogi Announces U.S. Availability of Mulpleta® (Lusutrombopag) for the Treatment of Thrombocytopenia in Adults with Chronic Liver Disease Scheduled to Undergo a Procedure[TPS : Biospace]
Jul 30,2018: Shionogi: Financial Results for the First Quarter of Fiscal Year 2018(Consolidated)
Jul 13,2018: Flu diagnosis kit ‘BRIGHTPOC Flu·Neo’ launched in Japan
May 09,2018: Shionogi : Financial Results for Fiscal Year 2017

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Shionogi & Co Ltd – Key Facts 6
Shionogi & Co Ltd – Key Employees 7
Shionogi & Co Ltd – Key Employee Biographies 10
Shionogi & Co Ltd – Major Products and Services 11
Shionogi & Co Ltd – History 13
Shionogi & Co Ltd – Company Statement 21
Shionogi & Co Ltd – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Joint Venture 24
Section 2 – Company Analysis 25
Company Overview 25
Shionogi & Co Ltd – Business Description 26
Shionogi & Co Ltd – Corporate Strategy 27
Shionogi & Co Ltd – SWOT Analysis 28
SWOT Analysis – Overview 28
Shionogi & Co Ltd – Strengths 28
Shionogi & Co Ltd – Weaknesses 29
Shionogi & Co Ltd – Opportunities 30
Shionogi & Co Ltd – Threats 31
Shionogi & Co Ltd – Key Competitors 32
Section 3 – Company Financial Ratios 33
Financial Ratios – Capital Market Ratios 33
Financial Ratios – Annual Ratios 34
Performance Chart 37
Financial Performance 37
Financial Ratios – Interim Ratios 38
Financial Ratios – Ratio Charts 39
Section 4 – Company’s Lifesciences Financial Deals and Alliances 40
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 40
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 41
Shionogi & Co Ltd, Recent Deals Summary 42
Section 5 – Company’s Recent Developments 43
Jul 30, 2018: Shionogi: Financial Results for the First Quarter of Fiscal Year 2018(Consolidated) 43
Jul 13, 2018: Flu diagnosis kit ‘BRIGHTPOC Flu・Neo’ launched in Japan 44
May 09, 2018: Shionogi : Financial Results for Fiscal Year 2017 45
Mar 22, 2018: Shionogi Announces Agreement with CARB-X for an Innovative AMR (Anti Microbial Resistance) Program 47
Mar 19, 2018: Shionogi to Announce Executive Appointments 48
Feb 28, 2018: Shionogi to Announce Corporate Reorganizations 49
Feb 05, 2018: Shionogi: Financial Results for the Third Quarter of Fiscal Year 2017(Consolidated) 50
Oct 13, 2017: The Dispute with the Boards of Appeal of the European Patent Office between Merck & Co., Inc. regarding HIV integrase inhibitor 51
Sep 21, 2017: Shionogi to Announce Personnel Reassignment 52
Jul 31, 2017: Shionogi Reports Revenue Of JPY75 Billion In Q1 Fiscal 2018 53
Section 6 – Appendix 54
Methodology 54
Ratio Definitions 54
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Shionogi & Co Ltd, Key Facts 6
Shionogi & Co Ltd, Key Employees 7
Shionogi & Co Ltd, Key Employee Biographies 10
Shionogi & Co Ltd, Major Products and Services 11
Shionogi & Co Ltd, History 13
Shionogi & Co Ltd, Other Locations 22
Shionogi & Co Ltd, Subsidiaries 23
Shionogi & Co Ltd, Joint Venture 24
Shionogi & Co Ltd, Key Competitors 32
Shionogi & Co Ltd, Ratios based on current share price 33
Shionogi & Co Ltd, Annual Ratios 34
Shionogi & Co Ltd, Annual Ratios (Cont...1) 35
Shionogi & Co Ltd, Annual Ratios (Cont...2) 36
Shionogi & Co Ltd, Interim Ratios 38
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 40
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 41
Shionogi & Co Ltd, Recent Deals Summary 42
Currency Codes 54
Capital Market Ratios 54
Equity Ratios 55
Profitability Ratios 55
Cost Ratios 56
Liquidity Ratios 56
Leverage Ratios 57
Efficiency Ratios 57

List of Figures
Shionogi & Co Ltd, Performance Chart (2014 - 2018) 37
Shionogi & Co Ltd, Ratio Charts 39
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 40
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 41

★海外企業調査レポート[Shionogi & Co Ltd (4507):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Neomed Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary Neomed Institute (Neomed) is a not-for-profit organization that provides drug discovery and development services. The organization spans its expertise in the development of small molecule therapeutics, biologics and vaccines. It offers chemistry, DMPK, fermentation and biology laboratories, …
  • Biocodex-製薬・医療分野:企業M&A・提携分析
    Summary Biocodex (Biocodex) is a drug manufacturing company that develops and commercializes drugs. The company offers products for gastro enteric diseases, pain management, neurological and psychiatric conditions, rheumatic pains, and ENT conditions. Its products include Saccharomyces boulardii, an …
  • Interconexion Electrica S.A. E.S.P.:発電所・企業SWOT分析
    Interconexion Electrica S.A. E.S.P. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Sorgenia SpA:電力:M&Aディール及び事業提携情報
    Summary Sorgenia SpA (Sorgenia) is an electricity generator and energy utilities company. The company operates in the energy and natural gas sector. It produces, imports, and sells electricity and gas. The company also offers various integrated power saving equipment and services. Sorgenia is a grou …
  • Fidelity National Financial Inc:企業の戦略・SWOT・財務情報
    Fidelity National Financial Inc - Strategy, SWOT and Corporate Finance Report Summary Fidelity National Financial Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • De’Longhi S.p.A. (DLG):企業の財務・戦略的SWOT分析
    De'Longhi S.p.A. (DLG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Par Pacific Holdings, Inc. (PARR)-石油・ガス分野:企業M&A・提携分析
    Summary Par Pacific Holdings, Inc. (Par Pacific), formerly known as Par Petroleum Corporation, manages, owns and maintains interests in energy and infrastructure related businesses. It has operations across the value chain from natural gas production to distribution and transportation. The company c …
  • ImmunoGen Inc (IMGN):製薬・医療:M&Aディール及び事業提携情報
    Summary ImmunoGen Inc (ImmunoGen) is a clinical-stage biotechnology company that focuses on the development of antibody-drug conjugate therapies for the treatment of cancer. The company’s lead product candidate, mirvetuximab soravtansine, a folate receptor alpha (FRa) intended for the treatment of p …
  • TD Ameritrade Holding Corporation:企業の戦略・SWOT・財務情報
    TD Ameritrade Holding Corporation - Strategy, SWOT and Corporate Finance Report Summary TD Ameritrade Holding Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • 3I Group Plc
    3I Group Plc - Strategy, SWOT and Corporate Finance Report Summary 3I Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Respiri Ltd (RSH):医療機器:M&Aディール及び事業提携情報
    Summary Respiri Ltd (Respiri), formerly iSonea Ltd, is a medical technology company that develops non-invasive medical devices and mobile health applications to improve the management of chronic respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). The company’s prop …
  • Azomures SA:企業の戦略的SWOT分析
    Azomures SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Verax Biomedical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Verax Biomedical Inc (Verax) is a developer of rapid tests for the detection of bacterial contaminants in tissues for transplantation, blood components, and cellular therapies. The company’s products include platelet pgd test, red cell pgd test and cell therapy PGD test. It uses the PGD tech …
  • Widex AS:企業の戦略的SWOT分析
    Widex AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Seven & i Holdings Co., Ltd.:戦略・SWOT・企業財務分析
    Seven & i Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Seven & i Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Verdezyne Inc-製薬・医療分野:企業M&A・提携分析
    Summary Verdezyne Inc (Verdezyne) is an industrial biotechnology company that develops and produces chemicals from renewable and non-food sources. The company’s products include adipic acid, dodecanedioic acid and sebacic acid. Its products are used in production of toothbrush bristles and fishing l …
  • CitiPower and Powercor:企業の戦略的SWOT分析
    CitiPower and Powercor - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Ameresco Inc (AMRC)-エネルギー分野:企業M&A・提携分析
    Summary Ameresco, Inc. (Ameresco) provides comprehensive energy services, including energy efficiency, infrastructure upgrades, asset sustainability and renewable energy solutions. It also offers energy infrastructure facility upgrade; and development, construction and operation of renewable energy …
  • JetBlue Airways Corp:企業の戦略・SWOT・財務情報
    JetBlue Airways Corp - Strategy, SWOT and Corporate Finance Report Summary JetBlue Airways Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Mabuhay Vinyl Corp (MVC):企業の財務・戦略的SWOT分析
    Mabuhay Vinyl Corp (MVC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆